Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress

Fried, 2003 N.C.f.H. Statistics National Health Interview Survey 2000, Centers for Disease Control and Prevention, Hyattsville, 2000, p. 92. Lusis, 2000, Atherosclerosis, Nature, 407, 233, 10.1038/35025203 Braunwald, 1997 Eagles, 1998, Non-pharmacological modification of cardiac risk factors: Part 3. Smoking cessation and alcohol consumption, J. Clin. Pharmacol. Ther., 23, 1, 10.1046/j.1365-2710.1998.00137.x Khot, 2003, Prevalence of conventional risk factors in patients with coronary heart disease, J. Am. Med. Assoc., 290, 898, 10.1001/jama.290.7.898 Steinberg, 1989, Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity, N. Engl. J. Med., 320, 915 Pasricha, 2002, When young hearts are broken: profiles of premature myocardial infarction, Am. Heart J., 143, 4, 10.1067/mhj.2002.120301 Ross, 1999, Atherosclerosis—an inflammatory disease, N. Engl. J. Med., 340, 115, 10.1056/NEJM199901143400207 Waart, 2001, Effect of glutathione S-transferase M1 genotype on progression of atherosclerosis in lifelong male smokers, Atherosclerosis, 158, 227, 10.1016/S0021-9150(01)00420-8 Li, 2000, Glutathione S-transferase genotype as a susceptibility factor in smoking-related coronary heart disease, Atherosclerosis, 149, 451, 10.1016/S0021-9150(99)00483-9 Miller, 2003, Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study, Atherosclerosis, 171, 265, 10.1016/j.atherosclerosis.2003.07.007 Clairmont, 1999, Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci, Carcinogenesis, 20, 1235, 10.1093/carcin/20.7.1235 Park, 2003, An association between NQO1 genetic polymorphism and risk of bladder cancer, Mut. Res., 536, 131, 10.1016/S1383-5718(03)00041-X Sachse, 2002, A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer, Carcinogenesis, 23, 1839, 10.1093/carcin/23.11.1839 Siegelmann-Danieli, 2002, Significance of genetic variation at the glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase 1 detoxification genes in breast cancer development, Oncology, 62, 39, 10.1159/000048245 Ross, 2000, NAD(P)H: quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms, Chemico-Biol. Interact., 129, 77, 10.1016/S0009-2797(00)00199-X Gilfix, 1997, Novel reductant for determination of total plasma homocysteine, Clin. Chem., 43, 687, 10.1093/clinchem/43.4.687 Kim, 2000, Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis, J. Urol., 164, 209, 10.1016/S0022-5347(05)67496-4 Chen, 1999, Association of the NAD(P)H:quinone oxidoreductase 609C→T polymorphism with a decreased lung cancer risk, Cancer Res., 59, 3045 Pepys, 2003, C-reactive protein: a critical update, J. Clin. Invest., 111, 1805, 10.1172/JCI200318921 Braunwald, 2008, Biomarkers in heart failure, N. Engl. J. Med., 358, 2148, 10.1056/NEJMra0800239 Rasouli, 2005, Plasma homocysteine predicts progression of atherosclerosis, Atherosclerosis, 181, 159, 10.1016/j.atherosclerosis.2005.01.001 Surekha, 2007, Oxidative stress and total antioxidant status in myocardial infarction, Singapore Med. J., 48, 137 Li, 2000, Glutathione S-transferase genotype as a susceptibility factor in smoking-related coronary heart disease, Atherosclerosis, 149, 451, 10.1016/S0021-9150(99)00483-9 Parsricha, 2002, When young hearts are broken: profiles of premature myocardial infarction, Am. Heart J., 143, 4, 10.1067/mhj.2002.120301 Masetti, 2003, Interactive effect of the glutathione S-transferase genes and cigarette smoking on occurrence and severity of coronary artery risk, J. Mol. Med., 81, 488, 10.1007/s00109-003-0448-5 Hong, 2007, Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer, Cancer Epidemiol. Biomarkers Prev., 16, 1784, 10.1158/1055-9965.EPI-07-0247 Tijhuis, 2008, NQO1 and NFE2L2 polymorphisms, fruit and vegetable intake and smoking and the risk of colorectal adenomas in an endoscopy-based population, Int. J. Cancer, 122, 1842, 10.1002/ijc.23246 Steiner, 1998, 606C→T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia, Cancer Lett., 135, 67, 10.1016/S0304-3835(98)00269-9 Ross, 2004, Quinone reductases multitasking in the metabolic world, Drug Metab. Rev., 36, 639, 10.1081/DMR-200033465 William, 2005, Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action, Environ. Mol. Mutagen., 45, 106, 10.1002/em.20095 Beall, 1996, Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin, Biochem. Pharmacol., 51, 645, 10.1016/S0006-2952(95)00223-5 Gibson, 1992, Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity, Mol. Pharmacol., 42, 531 Nygard, 1997, Plasma homocysteine levels and mortality in patients with coronary artery disease, N. Engl. J. Med., 337, 230, 10.1056/NEJM199707243370403 Ridker, 2001, Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events, N. Engl. J. Med., 344, 1959, 10.1056/NEJM200106283442601 Danesh, 2004, C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease, N. Engl. J. Med., 350, 1387, 10.1056/NEJMoa032804